Multiple sclerosis patients may soon benefit from StemGenex’s leading resource of adult adipose stem cells. StemGenex is now recruiting patients for a clinical trial investigating the regenerative potential of multiple sclerosis patients’ autologous stem cells derived from their own stromal vascular fraction.
“Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage,” commented principal investigator Dr. Jeremiah McDole, PhD, in a news release. “We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data.”
The trial will investigate a new, unique stem cell therapy that is potentially more effective than current stem cell therapies. Four targeted administration methods will be used to deliver stem cells across the blood brain barrier. Change from baseline on the Multiple Sclerosis Quality of Life Inventory will be the primary outcome measured after 12 months. An estimated 100 multiple sclerosis patients, ages 18 to 65 years, will be enrolled in the trial, which is projected to complete in May 2017.
“This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with multiple sclerosis,” said Rita Alexander, founder and president of StemGenex. “The average lifetime cost of current standard of care treatment per multiple sclerosis patient is $1.2 million. The human cost of the disease including pain and suffering endured by multiple sclerosis patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDole’s research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.”
StemGenex is committed to studying stem cell therapies in a variety of diseases, including diabetes, Alzheimer’s, Parkinson’s, and chronic obstructive pulmonary disease. “It is important patients have access to top-tier stem cell treatment,” said Joe Perricone, StemGenex Director of Patient Advocacy. “By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?